01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
17:29 , Mar 8, 2019 |  BC Week In Review  |  Company News

AbCellera, Denali to discover neurological disease antibodies

AbCellera will generate panels of antibodies against up to eight neurology targets selected by Denali using AbCellera’s high-throughput, ultra-deep single-cell immune profiling platform. Denali Therapeutics Inc. (NASDAQ:DNLI) will pay a technology access fee and research...
18:38 , Feb 5, 2019 |  BC Extra  |  Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

Serkan Kutan started in January as the CTO of the healthcare venture from J.P. Morgan (NYSE:JPM), Berkshire Hathaway Inc. (NYSE:BRK-A; NYSE:BRK-B) and Amazon.com Inc. (NASDAQ:AMZN). He was CTO of Zocdoc Inc. (New York, N.Y.), a...
19:25 , Jan 11, 2019 |  BC Week In Review  |  Company News

Sirion, Denali to develop AAVs that cross blood-brain barrier

Viral vector company Sirion Biotech GmbH (Martinsried, Germany) and neurology company Denali Therapeutics Inc. (NASDAQ:DNLI) partnered to develop adeno-associated virus (AAV) vectors that enable therapeutics to cross the blood-brain barrier to treat neurodegenerative diseases including...
23:49 , Nov 9, 2018 |  BC Extra  |  Company News

Management tracks: Denali, Convert

Neurology company Denali Therapeutics Inc. (NASDAQ:DNLI) appointed Jennifer Cook to its board. She is CEO of Grail Inc. (Menlo Park, Calif.) and previously was global head of clinical operations of Roche (SIX:ROG; OTCQX:RHHBY). Convert Pharmaceuticals...
00:10 , Nov 9, 2018 |  BioCentury  |  Finance

Biomatics’ next phase

Biomatics Capital plans to take a more active role in company formation and seek more neuroscience investments with its second fund, and has brought on two partners to implement its strategy. With Fund II, which...
18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
20:03 , Nov 2, 2018 |  BC Week In Review  |  Financial News

Arch to raise $600M for tenth fund

Arch Venture Partners is raising $600 million for its Arch Venture Fund X LP, according to an SEC filing. The firm declined to provide details, although the filing notes that no capital has been raised...